Veracyte
VCYT
193 hedge funds and large institutions have $1.52B invested in Veracyte in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 90 increasing their positions, 51 reducing their positions, and 34 closing their positions.
267% more call options, than puts
Call options by funds: $4.19M | Put options by funds: $1.14M
76% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 51
0.32% more ownership
Funds ownership: 108.07% → 108.39% (+0.32%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 205 → 193 (-12)
26% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 34
27% less capital invested
Capital invested by funds: $2.09B → $1.52B (-$566M)
Top Buyers
Top Sellers
VCYT Hedge Fund Activity: Q2 2022 in Review
193 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Veracyte (VCYT) for Q2 2022, worth a combined $1.52B — down 27% from $2.09B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of VCYT and 25 opened new positions — a net loss of 9 holders — while 51 trimmed existing stakes and 90 added.
The largest buyer was State Street, adding an estimated $24.2M. The largest seller was William Blair Investment Management, cutting an estimated $58.9M.
- 193 institutional investors held Veracyte (VCYT) as of Q2 2022, down from 205 in Q1 2022.
- Funds reported $1.52B of Veracyte stock for Q2 2022, down 27% quarter-over-quarter.
- 25 funds opened new Veracyte positions in Q2 2022 and 34 closed out, a net change of -9 holders.
- The largest Veracyte buyer in Q2 2022 was State Street, an estimated $24.2M added.
- The largest Veracyte seller in Q2 2022 was William Blair Investment Management, an estimated $58.9M sold.
Based on aggregated 13F filings for Q2 2022.